Brief: Molecular Templates Inc Says To Prioritize Next-Generation Etb Candidates

Molecular Templates

05/04/2021 12:12

April 5 (Reuters) - Molecular Templates Inc  MTEM.O :
    * MOLECULAR TEMPLATES TO PRIORITIZE NEXT-GENERATION ETB
CANDIDATES
    * MOLECULAR TEMPLATES INC - DEVELOPMENT OF FIRST-GENERATION
ETB
MT-3724 HAS BEEN DISCONTINUED
    * MOLECULAR TEMPLATES INC - TO FOCUS ON DEVELOPMENT OF
NEXT-GENERATION ETB PRODUCT CANDIDATES INCLUDING CLINICAL STAGE
MT-5111, TAK-169 AND MT-6402
    * MOLECULAR TEMPLATES INC - MOLECULAR TEMPLATES TO ASSUME
FULL
RIGHTS TO TAK-169, SECOND GENERATION ETB TARGETING CD38 FOR
TREATMENT OF MULTIPLE MYELOMA
    * MOLECULAR TEMPLATES INC - TAKEDA HAS COMMUNICATED THAT ITS
DECISION TO TURN OVER FULL RIGHTS OF TAK-169
    * MOLECULAR TEMPLATES INC - MTEM BELIEVES THAT TAK-169 IS A
POTENT
MOLECULE WITH A NOVEL MECHANISM OF ACTION IN MULTIPLE MYELOMA
    * MOLECULAR TEMPLATES INC - NO CHANGES TO TRIALS OR PLANS
FOR ANY
OTHER ETB PRODUCT CANDIDATES

Source text for Eikon:  ID:nGNX5l5ZC7 
Further company coverage:  MTEM.O 

 ((reuters.briefs@thomsonreuters.com;))